

September 16, 2026

**EN Otsuka Pharmaceutical Obtains Marketing Approval for
ENOFEED® Liquid for Enteral Use**

EN Otsuka Pharmaceutical Co., Ltd. (Head Office: Hanamaki, Iwate; President and Representative Director: Shuji Hashikawa; hereinafter “EN Otsuka Pharmaceutical”) announced that it obtained marketing approval in Japan on September 16, 2026, for ENOFEED® Liquid for Enteral Use (hereinafter “ENOFEED”), an enteral formula.

ENOFEED is an enteral formula for tube feeding with an energy density of 1.0 kcal/mL. It is formulated based on a daily energy intake of 900 kcal, taking into consideration the nutritional management of patients with low maintenance energy requirements.

Its energy-yielding nutrient balance was established based on the Dietary Reference Intakes for Japanese (2020), and the product contains iodine, selenium, chromium, and molybdenum. It also contains L-carnitine^{*1} and choline, taking into consideration the potential for deficiencies during long-term enteral nutritional management, as well as inulin^{*2} as a source of dietary fiber.

In addition, ENOFEED is supplied as a Ready to Hang (RTH) product that can be connected to a feeding set after opening without transferring the contents to another administration container.

Enteral formulas are widely used to provide nutritional support to postoperative patients and patients who have difficulty ingesting food orally over an extended period.

Older patients and patients with low levels of physical activity may be managed with relatively low maintenance energy intakes of approximately 1,000 kcal per day. In recent years, there has been a need in clinical settings for products designed with consideration for the nutritional management of patients with low maintenance energy requirements.

In response to these needs, ENOFEED has been formulated so that an intake of 900 kcal approximately meets the recommended dietary allowances or adequate intakes of vitamins and trace elements.

Further details regarding the National Health Insurance drug price listing and launch of ENOFEED will be announced once they have been determined.

EN Otsuka Pharmaceutical and Otsuka Pharmaceutical Factory, Inc., which is responsible for providing information on the product, will continue to provide products and information that contribute to appropriate nutritional management, with the aim of becoming the best partner for patients and healthcare professionals in the field of clinical nutrition worldwide.

Under its corporate philosophy, “Otsuka-people creating new products for better health worldwide,” the Otsuka group remains committed to contributing to the health of people around the world.

*1. L-carnitine: A micronutrient that plays an important role in energy production from lipids.

*2. Inulin: A water-soluble dietary fiber found in foods such as burdock root and onions. It is used in a variety of foods as a sweetener and food additive.

Product Information

Brand Name	ENOFEED® Liquid for Enteral Use
Regulatory Classification	None
Indications	Generally, this drug can be used to maintain nutritional status in postoperative patients; in particular, it is intended for nutritional support by tube feeding in patients with difficulty ingesting food orally over the long term.
Dosage and administration	The standard adult dosage is 900-1,500 mL (900-1,500 kcal) per day, administered by tube feeding. The administration rate should be 50-400 mL/hour, and the daily amount should be administered continuously or in several divided doses. Patients should be carefully observed when the product is administered for the first time. The dosage should be gradually increased, with close attention paid to clinical symptoms, so that the standard dosage is reached within several days. The dosage and administration rate should be adjusted as appropriate according to the patient's age, body weight, symptoms, and nutritional status.
Packaging	 15 bags [1 bag (300 mL) × 15]
Date of approval for manufacture and sale	September 16, 2026
Manufactured and distributed by	EN Otsuka Pharmaceutical Co., Ltd.
Comarketed by	Otsuka Pharmaceutical Factory, Inc. Otsuka Pharmaceutical Co., Ltd.

Corporate Profile

EN Otsuka Pharmaceutical Co., Ltd.

Established	:	March 26, 2002
Capital	:	JPY 1.51 billion
Representative	:	Shuji Hashikawa, President and Representative Director
Head Office	:	4-3-5 Nimaibashi, Hanamaki, Iwate Prefecture 025-0312, Japan
Employees	:	424 (as of December 31, 2025)
Business Description	:	Research & development, manufacturing, sales, and the export/import of enteral nutrients, foods for medical use, foods for the elderly, disease-specific foods
URL	:	https://www.enotsuka.co.jp

Otsuka Pharmaceutical Factory, Inc.

Incorporated	:	October 7, 1969 (founded September 1, 1921)
Capital	:	40.08 billion yen
Representative	:	Shuichi Takagi, President and Representative Director
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,432 (as of December 31, 2025)
Business Description	:	Manufacture, sale, import and export of clinical nutrition products and other pharmaceutical products, medical devices, functional foods, etc.
URL	:	https://www.otsukakj.jp/en/